Advertisement

Neuroradiology

, Volume 60, Issue 10, pp 1043–1051 | Cite as

Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns?

  • Michael H. Soike
  • Emory R. McTyre
  • Nameeta Shah
  • Ralph B. Puchalski
  • Jordan A. Holmes
  • Anna K. Paulsson
  • Lance D. Miller
  • Christina K. Cramer
  • Glenn J. Lesser
  • Roy E. Strowd
  • William H. Hinson
  • Ryan T. Mott
  • Annette J. Johnson
  • Hui-Wen Lo
  • Adrian W. Laxton
  • Stephen B. Tatter
  • Waldemar Debinski
  • Michael D. Chan
Functional Neuroradiology

Abstract

Purpose

For glioblastoma (GBM), imaging response (IR) or pseudoprogression (PSP) is frequently observed after chemoradiation and may connote a favorable prognosis. With tumors categorized by the Cancer Genome Atlas Project (mesenchymal, classical, neural, and proneural) and by methylguanine-methyltransferase (MGMT) methylation status, we attempted to determine if certain genomic or molecular subtypes of GBM were specifically associated with IR or PSP.

Methods

Patients with GBM treated at two institutions were reviewed. Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Mantel-cox test determined effect of IR and PSP on OS and PFS. Fisher’s exact test was utilized to correlate IR and PSP with genomic subtypes and MGMT status.

Results

Eighty-two patients with GBM were reviewed. The median OS and PFS were 17.9 months and 8.9 months. IR was observed in 28 (40%) and was associated with improved OS (median 29.4 vs 14.5 months p < 0.01) and PFS (median 17.7 vs 5.5 months, p < 0.01). PSP was observed in 14 (19.2%) and trended towards improved PFS (15.0 vs 7.7 months p = 0.08). Tumors with a proneural component had a higher rate of IR compared to those without a proneural component (IR 60% vs 28%; p = 0.03). MGMT methylation was associated with IR (58% vs 24%, p = 0.032), but not PSP (34%, p = 0.10).

Conclusion

IR is associated with improved OS and PFS. The proneural subtype and MGMT methylated tumors had higher rates of IR.

Keywords

Imaging response Pseudoprogression TCGA subtype Glioblastoma Radiomics 

Notes

Compliance with ethical standards

Funding

This study was funded in part by the Ben and Catherine Ivy Foundation (RP, GF: patient data collected from the Swedish Neuroscience Institute). The content is solely the responsibility of the respective authors and does not necessarily represent the official views of the Ben and Catherine Ivy Foundation.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

Informed consent

For this type of retrospective study formal consent is not required.

References

  1. 1.
    Dolecek TA, Propp JM, Stroup NE (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol 14(Suppl 5):v1–49.  https://doi.org/10.1093/neuonc/nos218 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMedGoogle Scholar
  3. 3.
    Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z (2015) Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 314:2535–2543CrossRefPubMedGoogle Scholar
  4. 4.
    Curran WJ Jr, Scott CB, Horton J et al (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704–710CrossRefPubMedGoogle Scholar
  5. 5.
    Hegi ME, Diserens A-C, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JEC, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003CrossRefPubMedGoogle Scholar
  6. 6.
    Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Zhang J, Yu H, Qian X, Liu K, Tan H, Yang T, Wang M, Li KC, Chan MD, Debinski W, Paulsson A, Wang G, Zhou X (2016) Pseudo progression identification of glioblastoma with dictionary learning. Comput Biol Med 73:94–101CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Gutman DA, Cooper LAD, Hwang SN, Holder CA, Gao JJ, Aurora TD, Dunn WD Jr, Scarpace L, Mikkelsen T, Jain R, Wintermark M, Jilwan M, Raghavan P, Huang E, Clifford RJ, Mongkolwat P, Kleper V, Freymann J, Kirby J, Zinn PO, Moreno CS, Jaffe C, Colen R, Rubin DL, Saltz J, Flanders A, Brat DJ (2013) MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology 267:560–569CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Barker FG 2nd, Prados MD, Chang SM et al (1996) Radiation response and survival time in patients with glioblastoma multiforme. J Neurosurg 84:442–448CrossRefPubMedGoogle Scholar
  10. 10.
    Brandes AA, Tosoni A, Spagnolli F, Frezza G, Leonardi M, Calbucci F, Franceschi E (2008) Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro-Oncology 10:361–367CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Shah N, Feng X, Lankerovich M, et al (2016) Data from Ivy GAP.  https://doi.org/10.7937/K9/TCIA.2016.XLWAN6NL
  12. 12.
    Clark K, Vendt B, Smith K, Freymann J, Kirby J, Koppel P, Moore S, Phillips S, Maffitt D, Pringle M, Tarbox L, Prior F (2013) The Cancer Imaging Archive (TCIA): maintaining and operating a public information repository. J Digit Imaging 26:1045–1057CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, DeGroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972CrossRefPubMedGoogle Scholar
  14. 14.
    Holmes JA, Paulsson A, Peiffer AM et al (2014) Genomic predictors of infield and marginal failure for glioblastoma treated with concurrent radiation therapy and temozolomide: a step towards personalized radiation fields? Radiat Oncol 90:S291–S292Google Scholar
  15. 15.
    Holmes JA, Paulsson AK, Page BR, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD (2015) Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design. J Neuro-Oncol 124:447–453CrossRefGoogle Scholar
  16. 16.
    Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    The Allen Brain Institute Ivy Glioblastoma Atlas Project. http://help.brain-map.org/display/glioblastoma/Documentation
  18. 18.
    Bady P, Sciuscio D, Diserens A-C, Bloch J, van den Bent MJ, Marosi C, Dietrich PY, Weller M, Mariani L, Heppner FL, Mcdonald DR, Lacombe D, Stupp R, Delorenzi M, Hegi ME (2012) MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol 124:547–560CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Noushmehr H, Weisenberger DJ, Diefes K et al (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510–522CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Kruser TJ, Mehta MP, Robins HI (2013) Pseudoprogression after glioma therapy: a comprehensive review. Expert Rev Neurother 13:389–403CrossRefPubMedGoogle Scholar
  21. 21.
    Hein PA, Eskey CJ, Dunn JF et al (2004) Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR Am J Neuroradiol 25:201–209PubMedGoogle Scholar
  22. 22.
    Geer CP, Simonds J, Anvery A, Chen MY, Burdette JH, Zapadka ME, Ellis TL, Tatter SB, Lesser GJ, Chan MD, McMullen KP, Johnson AJ (2012) Does MR perfusion imaging impact management decisions for patients with brain tumors? A prospective study. AJNR Am J Neuroradiol 33:556–562CrossRefPubMedGoogle Scholar
  23. 23.
    Tsuyuguchi N, Takami T, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Nishikawa M, Ohata K, Torii K, Morino M, Nishio A, Hara M (2004) Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery —in malignant glioma—. Ann Nucl Med 18:291–296CrossRefPubMedGoogle Scholar
  24. 24.
    Qian X, Tan H, Zhang J, et al (2016) Identification of biomarkers for pseudo and true progression of GBM based on radiogenomics study. Oncotarget 7(34):55377–55394.  https://doi.org/10.18632/oncotarget.10553
  25. 25.
    Proposed Decision Memo for Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer (CAG-00450N). https://www.cms.gov/medicare-coverage-database/details/nca-proposed-decision-memo.aspx?NCAId=290&bc=AAAAAAAAAAQAAA%3D%3D

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Michael H. Soike
    • 1
  • Emory R. McTyre
    • 1
  • Nameeta Shah
    • 2
  • Ralph B. Puchalski
    • 2
  • Jordan A. Holmes
    • 3
  • Anna K. Paulsson
    • 4
  • Lance D. Miller
    • 5
  • Christina K. Cramer
    • 1
    • 6
  • Glenn J. Lesser
    • 6
    • 7
  • Roy E. Strowd
    • 6
    • 8
  • William H. Hinson
    • 1
  • Ryan T. Mott
    • 9
  • Annette J. Johnson
    • 10
  • Hui-Wen Lo
    • 5
    • 6
  • Adrian W. Laxton
    • 6
    • 11
  • Stephen B. Tatter
    • 6
    • 11
  • Waldemar Debinski
    • 5
    • 6
  • Michael D. Chan
    • 1
    • 6
  1. 1.Department of Radiation OncologyWake Forest Baptist Medical CenterWinston-SalemUSA
  2. 2.The Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Neuroscience InstituteSeattleUSA
  3. 3.Department of Radiation OncologyUniversity of North Carolina School of MedicineChapel HillUSA
  4. 4.Department of Radiation OncologyUniversity of California San Francisco School of MedicineSan FranciscoUSA
  5. 5.Department of Cancer BiologyWake Forest Baptist Medical CenterWinston-SalemUSA
  6. 6.Brain Tumor Center of ExcellenceWake Forest Baptist Medical Center Comprehensive Cancer CenterWinston-SalemUSA
  7. 7.Department of Hematology & OncologyWake Forest Baptist Medical CenterWinston-SalemUSA
  8. 8.Department of NeurologyWake Forest Baptist Medical CenterWinston-SalemUSA
  9. 9.Department of PathologyWake Forest Baptist Medical CenterWinston-SalemUSA
  10. 10.Department of RadiologyWake Forest Baptist Medical CenterWinston-SalemUSA
  11. 11.Department of NeurosurgeryWake Forest Baptist Medical CenterWinston-SalemUSA

Personalised recommendations